2008-10-06 19:42:02 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/dce41c/malaysia_pharmaceu) has announced the addition of the "Malaysia Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
Our Malaysia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Malaysia's pharmaceuticals and healthcare industry.
For the Q308 update of the Malaysia Pharmaceuticals &
Healthcare report, the author has completely overhauled its drug market forecast model, which has resulted in many new data points through to 2012. Because the tool incorporates five macroeconomic variables, the country's disease burden and subjective analyst modification, the fundamental change is to the top-line projection. We now expect the value of pharmaceuticals (patented products + generic drugs + over-the-counter medicines) sold in Malaysia to reach US$1.52bn by 2012, which is slightly less than our Q208 forecast of US$1.82bn.
The Malaysian government risks further unpopularity if it goes ahead with plans to encourage individuals to contribute more to public healthcare funds. Because of rising state spending, a leading member of the ruling elite wants people to increase their social responsibility and buy more health insurance. Those that do will receive tax rebates. In line with the regional trend, the author believes that Malaysians will inevitably buy more health insurance over the medium term. However, after the recent protests over steep fuel price hikes, being told to do so will not go down well with electorate.
Due to their strength in innovative products, multinationals control about 70% of the pharmaceutical market, especially in terms of innovative and specialised products. All of the major multinational drug companies are represented in Malaysia, although only a small number have a direct manufacturing presence, largely as a result of restrictive regulatory practices. Companies with significant local production facilities are B Braun Pharmaceuticals, GlaxoSmithKline (GSK), Johnson & Johnson and Ranbaxy. Multinationals, which are primarily represented by the Pharmaceutical Association of Malaysia (PhAMA), are gradually getting involved in the fields of local biotechnology, clinical trials and bio-equivalence studies, illustrating the rising market potential as well as an improvement in operating conditions.
Continuing the regional trend, Malaysian doctors will soon be forced to stop dispensing medicines that they have prescribed. The topic is currently under debate, with all stakeholders - healthcare professionals, patients and the pharmaceutical industry - contributing their opinions on the potential new rules. The author strongly welcomes this separation of roles as there is a clear conflict of interest, but acknowledges that it may not be possible in remote parts of the country.
Key Topics Covered:
"Executive Summary
Malaysia Pharmaceuticals And Healthcare Industry SWOT
Malaysia Political SWOT
Malaysia Economic SWOT
Malaysia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Business Environment Rankings For Q308
Limits Of Potential Returns
Risks To Realisation Of Returns
Malaysia - Market Summary
Regulatory Regime
Recent Regulatory Developments
Intellectual Property Regime
Counterfeit Pharmaceuticals
Compulsory Licensing
Free Trade Agreements
Pricing And Reimbursement
Industry Trends And Developments
Epidemiology
Healthcare Sector
Pharmaceutical Sector
Pharmaceutical Demand
Domestic Company Activity
Halal Medicine
Traditional Medicine
Biotechnology And Research
Table: Key Points Of The Malaysian National Biotechnology Policy
Table: The Benefits Of Conducting Biotechnology Research In Malaysia
Recent Biotechnology Developments
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Expenditure And Prescription Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Key Growth Factors - Industry
Table: Malaysia's Health Expenditure Forecast Indicators
Key Growth Factors - Macroeconomic
Table: Malaysia - Economic Activity
Patented Market Forecast
Table: Malaysia Patented Drug Market Forecast Indicators
Generics Market Forecasts
Table: Malaysia's Generics Drugs Market Indicators, 2003-2012
OTC Market Forecast
Table: Malaysia's OTC Market Indicators, 2003-2012 (US$mn unless otherwise stated)
Export/Import Forecasts
Table: Malaysia Pharmaceuticals Exports And Imports Forecasts (US$mn)
Other Healthcare Data Forecasts
Table: Malaysia's Healthcare Data, 2003-2012
Key Risks To Our Forecast Scenario
Competitive Landscape
Table: Malaysia Pharmaceutical Market, Q406
Table: Leading Firms By 2005 Sales
Company Profiles
Multinational Companies
GlaxoSmithKline (GSK)
Pfizer
Novartis
Merck & Co
Sanofi-Aventis
Ranbaxy Malaysia
Eli Lilly Malaysia
Leading Indigenous Manufacturers
Pharmaniaga
Asia Pharmaceutical Products
Prime Pharmaceutical
Bumimedic
Hovid
Chemical Company of Malaysia (CCM)
Kotra Pharma
YSP Southeast Holding
Our Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned:
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Merck & Co
- Sanofi-Aventis
- Ranbaxy Malaysia
- Eli Lilly Malaysia
- Pharmaniaga
- Prime Pharmaceutical
- Bumimedic
- Hovid
- Chemical Company of Malaysia (CCM)
- Kotra Pharma
- YSP Southeast Holding
For more information visit
www.researchandmarkets.com/research/dce41c/malaysia_pharmaceu.
Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
